Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring (fibrosis) of lung tissue, ...
The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...
Increase in incidences of cancer worldwide and favorable reimbursement policies provided by manufacturers & insurance providers drive the growth of the market ...
EGEIRO Pharma (ISIN Code: BE0974387194 - Mnemonic: ALVET), a biopharmaceutical company specializing in the repositioning and reformulation of existing drugs, in particular for Idiopathic Pulmonary ...
RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from deadly lung diseases characterized by pulmonary inflammation, is pleased to announce ...